VANCOUVER, British Columbia — Acuitas Therapeutics, a global leader in lipid nanoparticle (LNP) delivery systems for advancing mRNA-based therapies, presented its Next-Generation LNP advancements at the 13th International mRNA Health Conference in Berlin. The suite of novel and enhanced technologies is designed to improve potency and safety, expand delivery beyond the liver, and broaden the therapeutic reach of mRNA-LNP medicines. The company also shared new preclinical data demonstrating further applications of its ALC-315 technology and improvements enabled by novel LNP formulations.
“Commercial validation of our technology has provided both an important milestone of success and the impetus for continued advancement,” said Dr. Thomas Madden, CEO of Acuitas Therapeutics. “Our research, presented at the mRNA Health Conference, is focused on two key goals: expanding the application of our technology into new therapeutic areas and enhancing the potency and safety of the platform itself, with novel LNP formulations and various improvement strategies. Underpinning both is our commitment to improving the translatability of preclinical data, which is essential for accelerating the journey of mRNA and personalized therapies from the laboratory bench to the clinic.”
During the conference, Acuitas’ Chief Scientific Officer, Dr. Ying Tam, delivered an oral presentation titled “Next-Generation Lipid Nanoparticles for Clinical Development of mRNA-based Therapeutics.” The presentation outlined the company’s strategy to improve LNP utility and applicability across several dimensions, including more potent LNP candidates achieving up to fourfold increases in some gene editing and vaccine applications, optimized lipid structures that reduce liver exposure and improve tolerability, and DARPin-conjugated LNPs enabling precise delivery to immune cells. Additional findings included mucous-penetrant mRNA-LNPs capable of delivering gene-editing payloads to airway epithelial cells in cystic fibrosis models, and a new pre-formed vesicle manufacturing approach that maintains potency while offering enhanced cost, storage, and flexibility benefits, particularly for personalized therapies.
These advancements demonstrate Acuitas’ commitment to pushing the boundaries of LNP science and expanding the therapeutic potential of mRNA-based medicines.
